What is Aclaris Therapeutics's G&A?

Aclaris Therapeutics (ACRS) reported G&A of $6.74M in Q1 2026.

How has Aclaris Therapeutics's G&A changed year-over-year?

Aclaris Therapeutics's G&A increased by 9.8% year-over-year, from $6.14M to $6.74M.

What is the long-term trend for Aclaris Therapeutics's G&A?

Over 4 years (2021 to 2025), Aclaris Therapeutics's G&A has grown at a -1.8% compound annual growth rate (CAGR), from $23.62M to $21.97M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Aclaris Therapeutics ACRS G&A

G&A at other companies

Corvus PharmaceuticalsCRVS

$3.7M+49.9%

Upstream Bio, Inc.UPB

$8.08M+19.2%

Avalo TherapeuticsAVTX

$6.85M+23.6%

Shattuck Labs, Inc.STTK

$4.6M+2.9%

Apogee Therapeutics, Inc.APGE

$21.95M+31.4%

Kymera TherapeuticsKYMR

$20.36M+25.1%

Segments

By segment

See full

Single Reportable$6.74M—

Other financials

Income statement

See full

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

See full

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

See full

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

See full

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

See full

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aclaris Therapeutics's G&A?: Aclaris Therapeutics (ACRS) reported G&A of $6.74M in Q1 2026.
How has Aclaris Therapeutics's G&A changed year-over-year?: Aclaris Therapeutics's G&A increased by 9.8% year-over-year, from $6.14M to $6.74M.
What is the long-term trend for Aclaris Therapeutics's G&A?: Over 4 years (2021 to 2025), Aclaris Therapeutics's G&A has grown at a -1.8% compound annual growth rate (CAGR), from $23.62M to $21.97M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.